Small-molecule Malaria treatment and prevention strategy
- Summary
- Malaria has created a global health crisis that affects 500 million people worldwide each year. The parasite that causes malaria, Plasmodium falciparum, is adaptive and readily develops drug resistance. Therefore, there is a pressing need to develop new treatments as existing treatments become increasingly obsolete. This technology is a library of small-molecules that inhibit a target protein, Equilibrative Nucleoside Transporter 1 (PfENT1), preventing the parasite's proliferation. These compounds provide a strategy for developing new malaria treatments and preventative therapeutics.
- Technology Benefits
- PfENT1 is a drug target for the malaria parasite, P. falciparumPatent Information:Patent Pending (WO/2014/210319)Tech Ventures Reference: IR CU13311
- Technology Application
- Potential drug treatment for malaria and cerebral malariaPotential prophylaxis for malariaPotential drug target for other parasitic diseasesBasic research on PfENT1 inhibition
- Detailed Technology Description
- None
- *Abstract
-
None
- *Inquiry
- Jerry KokoshkaColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU13311
- *Principal Investigator
-
- *Publications
- Frame IJ, Deniskin R, Rinderspacher A, Katz F, Deng SX, Moir RD, Adjalley SH, Coburn-Flynn O, Fidock DA, Willis IM, Landry DW, Akabas MH. ”Yeast-Based High-Throughput Screen Identifies Plasmodium falciparum Equilibrative Nucleoside Transporter 1 Inhibitors That Kill Malaria Parasites.” ACS Chem Biol. 2015 Jan 30. [Epub ahead of print]
- Country/Region
- USA
For more information, please click Here
